drugset / Trial / NCT03573882

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882

Phase 3 Terminated 179 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

Timeline

Start
2018-06-06
Primary completion
2024-11-12
Completion
2024-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Voxelotor Small molecule 900 mg Oral
Subject Voxelotor Small molecule 1500 mg Oral

Indications